A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma-Reference-Cited by-同舟云学术

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

Published:2018-01-25 Issue:4 Volume:131 Page:397-407
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Amengual Jennifer E.¹^ORCID,Lichtenstein Renee¹,Lue Jennifer¹,Sawas Ahmed¹,Deng Changchun¹,Lichtenstein Emily¹,Khan Karen¹,Atkins Laine¹,Rada Aishling¹,Kim Hye A.¹,Chiuzan Codruta²,Kalac Matko¹,Marchi Enrica¹,Falchi Lorenzo¹,Francescone Mark A.³,Schwartz Lawrence³,Cremers Serge⁴,O’Connor Owen A.¹

Affiliation:

1. Center for Lymphoid Malignancies, Columbia University Irving Medical Center, New York, NY;

2. Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY; and

3. Department of Radiology and

4. Division of Clinical Pathology, Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY

Abstract

Key Points The combination of romidepsin and pralatrexate is safe and well tolerated in patients with relapsed/refractory lymphoma. The combination led to an overall response rate of 71% (10/14, with 4/14 complete responses) in patients with relapsed/refractory T-cell lymphoma.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/4/397/1465788/blood806737.pdf

Reference32 articles.

1. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States;Abouyabis;Leuk Lymphoma,2008

2. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma;Fisher;N Engl J Med,1993

3. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01;d’Amore;J Clin Oncol,2012

4. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group;Schmitz;Blood,2010

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peripheral T-cell lymphoma: From biology to practice to the future;Cancer Treatment Reviews;2024-09

2. A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed/refractory AITL;Frontiers in Immunology;2024-06-25

3. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma;Journal of Hematology & Oncology;2024-06-01

4. Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma;Blood Advances;2024-05-29

5. Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders;Biomedicines;2024-04-29